Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...

Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The ...

For men, high levels of physical activity and fitness are associated with reduced risk of amyotrophic lateral sclerosis (ALS).

Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is cutting 73% of jobs.

Biopharma innovator Alchemab Therapeutics, whose labs are in Cambridge UK, is collaborating with multinational pharma giant ...

A variant of the virus caused disease in people in 1997, when there was a small but deadly outbreak in Hong Kong. Eighteen ...

Equities research analysts at StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV – Get Free Report) in a note ...

A former president of the Whistler Resort Association, and alderman on Whistler’s original council, Raine died last month at ...

Richard M. Cohen, an outspoken and award-winning television news producer whose career was ultimately derailed by the ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...

Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, ...